

Table SI. Pegylated interferon alpha-2a-treated patients: clinical data

Patient/ Diagnosis	Age/Sex	Disease stage		Disease duration ^c	B-stage ^a	Ocular SE	Symptoms	Cardio vascular risk factors/ events (11)
		Initial	Course ^a					
1/MF	71 ^a /Male	IIIB	IVA	3 years	B0	Central retinal artery occlusion, left eye	Left eye: Complete vision loss	Hypertension, tobacco use, hyper-cholesterolaemia, hypertriglyceridaemia
2/SS	71 ^a /Female	IVA	IVA	6 months	B1	Multiple infarcts of nerve fibre bundles, retina on both sides	Left eye: Blurred vision, lint-like structure in the field of vision	No
3/SS	72 ^a /Female	IIIB	IVA1	5 years	B1	Massive vision loss (visual acuity, cc: 0.1 RE, 0.4 LE) due to sicca syndrome	Both eyes: Partial vision loss	No
4/SS	61 ^b /Male	IVA1	-	-	-	None	-	Diabetes mellitus, hypertension, hyper-cholesterolaemia, hypertriglyceridaemia, coronary heart disease, coronary vessel stent, heart failure, stroke, myocardial infarction

^aAt time of diagnosis of ocular SE, ^bat time of PEG-IFN α -2a treatment initiation, ^cuntil ocular SE occurred.
MF: mycosis fungoides; SS: Sézary syndrome; RE: right eye; LE: left eye.

Table SII. Pegylated interferon alpha-2a-treated patients: treatment

Patient	Duration of therapy		Medication	Changes due to ocular SE	ECP		Previous CTCL-treatments ^b
	IFN α -2a	PEG-IFN α -2a			Before ocular SE	After ocular SE	
1	20 months	3 days	ASA; macrogol; pantoprazole; triamterene/ hydrochlorothiazide; pravastatin; ramipril, PEG-IFN α -2a, co-medication with paracetamol; thiamazole Supplements; various inhalers	PEG-IFN α -2a discontinued	Yes (for 14 months ^a)	Yes	IFN α -2a partly + ECP
2	2 months	2 months	Levothyroxine; cholecalciferol; promethazine; PEG-IFN α -2a, co-medication with paracetamol	PEG-IFN α -2a discontinued New medication: ASA	Yes (for 4 months ^a)	Yes	Systemic PUVA + MTX Alitretinoin (for only 1 week) ECP + IFN α -2a
3	15 months	5 months	Iodide; ioperamide; PEG-IFN α -2a, co-medication with paracetamol; MF; amitriptyline; gabapentin	PEG-IFN α -2a discontinued New medication: ASA	Yes (for 27 months ^a)	Yes	ECP DMF ECP + DMF ECP + IFN α -2a and partly + DMF
4	12 years	6.5 months	ASA; bisoprolol; tamsulosin; ramipril; spironolactone; pancrelipase capsules; atorvastatin; allopurinol; pantoprazole; insulin glargine; human insulin; PEG-IFN α -2a, co-medication with paracetamol; torasemide; supplements	-	Yes (for >12 years ^a)	No	ECP + systemic PUVA ECP + systemic PUVA + IFN α -2a ECP + IFN α -2a

All patients received IFN α -2a therapy in advance. Therapy was switched to PEG-IFN α -2a after IFN α -2a therapy was no longer available.

^auntil ocular SE occurred, ^bsorted chronologically.

Pt.: patient; Dx: diagnosis; MF: mycosis fungoides; SS: Sézary syndrome; IFN α -2a: interferon alpha-2a; PEG-IFN α -2a: pegylated IFN α -2a; SE: side-effects; cc: cum correctione; RE: right eye; LE: left eye; d: days; mo: months; yr: years; ASA: acetylsalicylic acid; ECP: extracorporeal photopheresis; CTCL: Cutaneous T-cell lymphomas; PUVA: psoralen plus ultraviolet A light; MTX: methotrexate; DMF: dimethyl fumarate